WHO reportedly added two vaccines to its prequalification list in recent weeks.
Sanofi’s meningococcal ACYW tetanus toxoid-based conjugate vaccine, MenQuadfi, notched PQ status last month, according to WHO records.
Meanwhile, a CNBG announcement last week on Chinese social media stated that its Sabin-based inactivated polio vaccine (sIPV) had won the designation. With this approval, CNBG’s shot beats out Sinovac’s product to become the second prequalified sIPV after LG Chem’s…
Sanofi announced last week that the U.S. FDA has approved MenQuadfi, its meningococcal ACYW tetanus toxoid-based conjugate vaccine. The approval expands the company’s U.S. meningitis portfolio to people 56 years and older, a demographic not previously covered by Sanofi’s existing diphtheria toxoid-based quadrivalent product, Menactra.
Gavi issued a press release last week detailing decisions from its November 2018 board meeting.
Leading the announcements, Gavi said it had provisionally approved support for six new programs as part of its latest Vaccine Investment Strategy. These were a hepatitis B birth dose, diphtheria, pertussis and tetanus-containing boosters, an oral cholera vaccine (OCV), a post-exposure rabies vaccine, a multivalent meningococcal conjugate vaccine, and a respiratory syncytial virus vaccine.…
Local media reported this week that Malaysia’s state-backed Pharmaniaga Bhd plans to invest $25 million over the next two to three years to manufacture halal vaccines. Supporting Pharmaniaga are India’s Hilleman Laboratories, which will provide vaccine “know-how and technologies,” and Malaysia’s Technology Depository Agency, which will coordinate vaccine development efforts. The Star newspaper said the company will start with diphtheria, tetanus and acellular pertussis and meningococcal…